iPS Cells & Regenerative Medicine– category –
-
Japan Approves Edostiladrin Gene Therapy for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer, Offering Bladder Preservation
Oncolo.jp Japan Overview Ferring Pharmaceuticals has received manufacturing and marketing approval in Japan for Edostiladrin (nadofaragene firadenovec), a gene therapy for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NM... -
Japan Approves Pricing for World’s First iPSC-Derived Product, Amchepry, Signaling New Era for Regenerative Medicine
薬事日報 Japan Overview Japan's Central Social Insurance Medical Council has approved the official drug pricing for three new regenerative medicine products, including Sumitomo Pharma's iPSC-derived dopamine neural progenitor cells, Amch... -
Genprex Collaborators Report Positive Preclinical Data for Diabetes Gene Therapy at ASGCT 2026, Showing Alpha-to-Beta Cell Reprogramming
PR Newswire USA Overview Genprex's collaborators presented positive preclinical data at ASGCT 2026 for GPX-002, a gene therapy candidate for Type 2 Diabetes (T2D). The therapy, which delivers Pdx1/MafA genes to the pancreas via an AAV ve... -
Precision BioSciences Unveils Promising Preclinical Data for In Vivo Gene Editing Therapy in Duchenne Muscular Dystrophy
Morningstar USA Overview Precision BioSciences has presented encouraging preclinical data for PBGENE-DMD, an in vivo gene editing therapy targeting Duchenne Muscular Dystrophy, at the 2026 ASGCT Annual Meeting. Early intervention in youn...
